Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC).

Authors: William Kevin Kelly, Michael J. Morris, Lisa Horvath, Viktor Grünwald, Alton Oliver Sartor, Johann S. De Bono, Karim Fizazi, Kim N. Chi, Joaquin Mateo, Joshua Kapp, Zhao Yang, Nobuaki Matsubara

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps5118

Source: Full article

---

Abstract

TPS5118